ResearcherAnhui Medical UniversityNo recent work listed

Lei Zhao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4048-5949; OpenAlex author ID A5101929506. Sources: OpenAlex.

Their work

Papers: 3 (first author 3, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper

Papers 3

Metabolic Reprogramming：Application of lipid metabolism related genes in the risk model of clinical prognosis of pancreatic cancer First author DOI 10.21203/rs.3.rs-3744911/v1 ↗
IL-39 acts as a friend to pancreatic cancer. First author DOI 10.1007/s12032-018-1236-y ↗
IL-33 acts as a foe to MIA PaCa-2 pancreatic cancer. First author DOI 10.1007/s12032-016-0880-3 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Tao Zhang · 1 shared paper, 2023 · strength 0.39
- Paper Metabolic Reprogramming：Application of lipid metabolism related genes in the risk model of clinical prognosis of pancre… DOI 10.21203/rs.3.rs-3744911/v1 ↗
Yujiang Fang · 2 shared papers, 2017–2018 · strength 0.14
- Paper IL-39 acts as a friend to pancreatic cancer. DOI 10.1007/s12032-018-1236-y ↗
- Paper IL-33 acts as a foe to MIA PaCa-2 pancreatic cancer. DOI 10.1007/s12032-016-0880-3 ↗
Alicia A. Manning · 1 shared paper, 2018 · strength 0.08
- Paper IL-39 acts as a friend to pancreatic cancer. DOI 10.1007/s12032-018-1236-y ↗
Michael B. Nicholl · 1 shared paper, 2017 · strength 0.06
- Paper IL-33 acts as a foe to MIA PaCa-2 pancreatic cancer. DOI 10.1007/s12032-016-0880-3 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.